{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:05:12Z","timestamp":1768518312216,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1038\/s41391-021-00422-4","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T12:02:46Z","timestamp":1626091366000},"page":"666-671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2047-496X","authenticated-orcid":false,"given":"Takuma","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Hirama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Mitsuzuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Naya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Tsukino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyoshi","family":"Hashine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukuta","family":"Fumimasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yokomizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3884-8915","authenticated-orcid":false,"given":"Yoichiro","family":"Tohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"422_CR1","unstructured":"Ferlay JEM, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2018."},{"key":"422_CR2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","volume":"70","author":"LP Bokhorst","year":"2016","unstructured":"Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, et al. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol. 2016;70:954\u201360.","journal-title":"Eur Urol"},{"key":"422_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1464-410X.2012.11658.x","volume":"111","author":"K Mitsuzuka","year":"2013","unstructured":"Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, et al. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the prostate cancer international: active surveillance criteria. BJU Int. 2013;111:914\u201320.","journal-title":"BJU Int"},{"key":"422_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00345-014-1453-8","volume":"33","author":"M Sugimoto","year":"2015","unstructured":"Sugimoto M, Hirama H, Yamaguchi A, Koga H, Hashine K, Ninomiya I, et al. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. World J Urol. 2015;33:981\u20137.","journal-title":"World J Urol"},{"key":"422_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JU.0000000000000693","volume":"203","author":"A Amin","year":"2020","unstructured":"Amin A, Scheltema MJ, Shnier R, Blazevski A, Moses D, Cusick T, et al. The magnetic resonance imaging in active surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies. J Urol. 2020;203:910\u20137.","journal-title":"J Urol"},{"key":"422_CR6","doi-asserted-by":"publisher","first-page":"101042831879925","DOI":"10.1177\/1010428318799255","volume":"40","author":"A Carneiro","year":"2018","unstructured":"Carneiro A, Priante Kayano P, Gomes Barbosa AR, Langer Wroclawski M, Ko Chen C, Cavlini GC, et al. Are localized prostate cancer biomarkers useful in the clinical practice? Tumour Biol. 2018;40:1010428318799255.","journal-title":"Tumour Biol"},{"key":"422_CR7","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/clinchem\/37.9.1618","volume":"37","author":"H Lilja","year":"1991","unstructured":"Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37:1618\u201325.","journal-title":"Clin Chem"},{"key":"422_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S0090-4295(97)00449-4","volume":"50","author":"SD Mikolajczyk","year":"1997","unstructured":"Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology. 1997;50:710\u20134.","journal-title":"Urology"},{"key":"422_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0090-4295(03)00138-9","volume":"62","author":"TY Chan","year":"2003","unstructured":"Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW, et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology. 2003;62:177\u201381.","journal-title":"Urology"},{"key":"422_CR10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.juro.2009.12.056","volume":"183","author":"BV Le","year":"2010","unstructured":"Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010;183:1355\u20139.","journal-title":"J Urol"},{"key":"422_CR11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.juro.2010.12.032","volume":"185","author":"WJ Catalona","year":"2011","unstructured":"Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng\/ml prostate specific antigen range. J Urol. 2011;185:1650\u20135.","journal-title":"J Urol"},{"key":"422_CR12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2013.01.011","volume":"63","author":"M Lazzeri","year":"2013","unstructured":"Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng\/ml: a multicentric European study. Eur Urol. 2013;63:986\u201394.","journal-title":"Eur Urol"},{"key":"422_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.juro.2012.06.009","volume":"188","author":"JJ Tosoian","year":"2012","unstructured":"Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, et al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol. 2012;188:1131\u20136.","journal-title":"J Urol"},{"key":"422_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00432-013-1566-2","volume":"140","author":"H Hirama","year":"2014","unstructured":"Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y. The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol. 2014;140:257\u201363.","journal-title":"J Cancer Res Clin Oncol"},{"key":"422_CR15","doi-asserted-by":"publisher","unstructured":"Hirama H, Sugimoto M, Miyatake N, Kato T, Venderbos LDF, Remmers S, et al. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN. World J Urol. 2020. https:\/\/doi.org\/10.1007\/s00345-020-03494-4. Online ahead of print.","DOI":"10.1007\/s00345-020-03494-4"},{"key":"422_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7326\/M13-2841","volume":"160","author":"AJ Vickers","year":"2014","unstructured":"Vickers AJ, Pepe M. Does the net reclassification improvement help us evaluate models and markers? Ann Intern Med. 2014;160:136\u20137.","journal-title":"Ann Intern Med"},{"key":"422_CR17","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1136\/bmj.i6","volume":"352","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;352:i6.","journal-title":"BMJ"},{"key":"422_CR18","doi-asserted-by":"publisher","first-page":"e67687","DOI":"10.1371\/journal.pone.0067687","volume":"8","author":"M Ferro","year":"2013","unstructured":"Ferro M, Bruzzese D, Perdon\u00e0 S, Marino A, Mazzarella C, Perruolo G, et al. Prostate health index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng\/ml. PLoS One. 2013;8:e67687.","journal-title":"PLoS One"},{"key":"422_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.4111\/icu.2016.57.5.336","volume":"57","author":"PK Chiu","year":"2016","unstructured":"Chiu PK, Teoh JY, Lee WM, Yee CH, Chan ES, Hou SM, et al. Extended use of prostate health index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng\/mL and normal digital rectal examination. Investig Clin Urol. 2016;57:336\u201342.","journal-title":"Investig Clin Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00422-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00422-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00422-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:04:21Z","timestamp":1673525061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00422-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1038\/s41391-021-00422-4","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"13 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All study participants provided informed consent. This study was performed in accordance with the ethical standards established by the Declaration of Helsinki and was approved by the Kagawa University Ethics committee (approval number: H24-084). This study was registered in the University Hospital Medical Information Network\u2014Clinical Trial Registry (UMIN-CTR) (UMIN 000009876).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}